The UK-India Free Trade Agreement (FTA) officially took effect in mid-July 2026, eliminating or reducing tariffs on up to 99% of UK goods entering India and 90% of Indian goods entering the UK, with broad coverage including medical technology.

Initial tariff removals cover about two-thirds of tariff lines for UK exports to India, with 85% of qualifying lines becoming duty-free after a transition period; sectors such as machinery, medical technology, consumer goods, automobiles, and alcoholic beverages benefit, though cars face limited concessions under quotas.

Indian tariff lines see strong relief as roughly 90% are reduced or eliminated, and 92% of current British imports from India qualify for concessions, boosting bilateral trade flows in textiles, garments, leather, footwear, marine products, processed foods, gems and jewelry, pharmaceuticals, and engineering goods.

Digital health and data interoperability are prioritized, showcasing NHS-linked digital records, autonomous AI for hospital workflows, and health app assessments to reduce fragmentation and improve data flow.

The agreement is expected to spur two-way investment, deepen technology collaboration, and broaden professional services, with stronger ties in financial services, education, healthcare, renewable energy, and innovation.

Over 3–5 years, growth is projected in digital health, virtual care, diagnostics, data-enabled decision-making, and robotics/precision interventions, focusing on scalable, affordable solutions for India.

An implementation ceremony in Mumbai underscored immediate commercial benefits and stressed that the pact aims to deliver real-world gains, beyond symbolism.

The deal is seen as boosting supply-chain resilience by encouraging diversification and positioning India as a key manufacturing hub for UK firms, while opening Indian manufacturers to sophisticated British markets and networks.

Indian firms are encouraged to engage with the UK DBIST at the British High Commission to explore co-development, manufacturing, and market-expansion partnerships under the FTA.

CETA forms part of the broader India-UK Vision 2035, aligning trade with technology, climate, education, and security cooperation through binding commitments and collaborative plans.

Pilot-ready collaboration pathways include voluntary licensing, technology transfer, joint R&D and clinical validation through academia–industry partnerships, and scale manufacturing under preferential tariffs for UK-origin innovations in India.

UK medtech leaders highlighted include CMR Surgical, Smith+Nephew, Luma Robotics, Oxford Nanopore, Occuity, Virtual Autopsy UK, among others, emphasizing diagnostics, prevention, and data-enabled care.